Effects of @entity1481 on @entity5649 in isolated perfused XXXX hearts.

@entity1 @entity5649 @entity35 @entity63 @entity1481 @entity2904
@entity1481 (1-[2,3,4-trimethoxibenzyl)]-piperazine, @entity2904 ) is a drug with a proposed metabolically based antiischemic action. Because @entity5649 is a serious complication of @entity63 and is considered metabolic in origin, we studied the effect of @entity1481 ( @entity2904 ) on development of @entity5649 in experimental low-flow @entity63 . @entity2904 was either added to the perfusion fluid or given as pretreatment to the donor @entity35 . Langendorff-perfused isolated @entity35 hearts were submitted to 30-min subtotal global @entity63 (residual flow = 0.2 ml/min, n = 6 per group) (normal flow = 12.4 +/- 0.8 ml/min, heart fresh weight = 0.9 +/- 0.3 g). @entity5649 was measured by a water-filled intraventricular balloon. Thereafter, the hearts were reperfused for 20 min and recovery of intraventricular pressure was monitored. Furthermore, because the mechanisms of action of @entity2904 may involve cellular energy metabolism, we assessed throughout glycolytic flux by collecting the coronary effluent every 5 min during control perfusion, @entity63 , and reperfusion periods. Animals from the pretreated groups received @entity2904 [3 mg/kg orally (p.o.) twice daily] for 5 days. Animals from the control group received placebo for the same time period. Concentrations of 10(-6) and 10(-4) M were used when the drug was added to the perfusate. In our experimental conditions, @entity2904 pretreatment alone had no measurable cardioprotective effect, but addition to the perfusate of @entity2904 10(-6) M, approximately a therapeutic concentration in @entity1 , reduced @entity5649 in both pretreated and control groups and improved postischemic recovery of developed pressure.(ABSTRACT TRUNCATED AT 250 WORDS)
